Healthpeak Properties, Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Healthpeak Properties, Inc. is a healthcare-focused REIT operating in three reportable segments: outpatient medical, lab, and senior housing. The quarter was defined by the completion of the Janus Living, Inc. IPO on March 23, 2026, which spun off the senior housing portfolio into a publicly traded entity while Healthpeak retained an 81.6% controlling interest and continues to consolidate Janus Living.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $752.95 million | $702.89 million |
| Net Income (Applicable to Common Shares) | $193.48 million | $42.36 million |
| Earnings Per Share (Diluted) | $0.28 | $0.06 |
| Net Cash Provided by Operating Activities | $260.88 million | $279.43 million |
| Total Debt (Carrying Value) | $10.42 billion | $9.85 billion (approx.) |
| Cash and Cash Equivalents | $1.17 billion | $0.47 billion |
| Adjusted NOI (Total Portfolio) | $339.40 million | $343.58 million |
Material Changes vs. Prior Period
- Significant Gains on Change of Control: Net income surged primarily due to non-recurring gains totaling approximately $138 million. This includes a $92 million gain from the sale of an 80% interest in six outpatient medical buildings (BX JV I and II) and a $46 million gain from the buyout of the Sovereign Wealth Fund Senior Housing JV (SWF SH JV).
- Segment Performance:
- Senior Housing: Revenues increased to $200.3 million (from $148.9 million) and Adjusted NOI rose to $55.4 million, driven by the SWF JV buyout and new acquisitions.
- Lab: Adjusted NOI decreased to $141.0 million (from $146.2 million) due to lower occupancy and dispositions.
- Outpatient Medical: Adjusted NOI increased slightly to $198.4 million (from $197.3 million) due to lease renewals and escalations.
- Transaction Costs: Increased to $24.1 million (from $5.5 million) largely due to costs associated with the Janus Living IPO.
- Interest Expense: Rose to $87.3 million (from $72.7 million) due to new senior unsecured note issuances in 2025 and higher commercial paper borrowings.
Guidance, Outlook, and Risks
- Janus Living IPO: The IPO generated $966 million in gross proceeds. Healthpeak received Janus Living stock and OP units, retaining control. Janus Living established a $500 million revolving credit facility and a $100 million term loan, both undrawn as of quarter-end.
- Capital Allocation: The company repurchased 5.95 million shares in April 2026 (post-period) for $100 million. $306 million remains available under the 2024 Share Repurchase Program.
- Liquidity: Cash balances increased significantly to $1.17 billion, bolstered by IPO proceeds and financing activities. The company maintains investment-grade credit ratings (Baa1/BBB+).
- Risks: Key risks include interest rate volatility, potential tenant insolvency, regulatory changes in healthcare reimbursement, and the integration risks associated with the Janus Living IPO structure.
Investor Verification Checklist
- Gain Sustainability: Verify the extent to which Q1 2026 net income is driven by one-time "change of control" gains ($138 million) versus recurring operational cash flow.
- Janus Living Consolidation: Confirm the ongoing consolidation of Janus Living and the impact of the 18.4% public noncontrolling interest on future earnings attribution.
- Debt Maturities: Review the debt maturity schedule, noting $893 million due in 2026 and the reliance on commercial paper ($1.75 billion outstanding) which is backstopped by the revolving facility.
- Lab Segment Occupancy: Monitor the Lab segment's occupancy rate, which dropped to 88.3% (Total Portfolio) from 97.9% in the prior year, impacting Adjusted NOI.
- Dividend Coverage: Assess the ability to maintain the monthly dividend of $0.10167 per share given the increase in interest expense and transaction costs.